Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 17;173(5):693–702. doi: 10.1530/EJE-15-0500

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The authors

Inline graphic This work is licensed under a Creative Commons Attribution 3.0 Unported License

PMC Copyright notice

Effect of pegvisomant (PEG) on the apnea–hypopnea index (AHI) in 12 patients. Upper panel (A): individual IGF1 values in 12 patients before and during treatment with pegvisomant. IGF1 normalized (<115% ULN) in 10/12 patients (83%). Lower panel (B): changes in AHI on pegvisomant. Dotted lines represent the different stages of obstructive sleep apnea (OSA). Before pegvisomant: severe OSA (AHI >30/h, n=3), moderate OSA (15<AHI≤30/h, n=2), mild OSA (5<AHI≤15/h, n=4), no OSA (AHI≤5/h, n=3). On pegvisomant: severe OSA (n=1), moderate OSA (n=2), mild OSA (n=5), no OSA (n=5). Statistical significance: *P<0.05 (before pegvisomant vs on pegvisomant).